Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Lacosamide is a functionalized amino acid with antinociceptive properties in inflammatory and
neuropathic pain, and displays a unique mechanism: it enhances slow inactivation of Nav1.3,
Nav1.7, and Nav1.8.
Nav1.7 is expressed predominantly in nociceptive and sympathetic neurons. Gain-of-function
mutations have been described in Nav1.7 that result in extreme pain disorders such as
SCN9A-associated small fiber neuropathy. In the disease states genetically linked to a
gain-of-function of Nav1.7, the sodium channel is mutated to increase the sodium influx
resulting in a hyperexcitable sensory neuron, and a resultant sensation of pain.
The objective of the study is to determine the efficacy and safety of lacosamide, a sodium
channel blocker, in patients with pain due to SCN9A-associated small fiber neuropathy.